Assembly of poliovirus virions requires proteolytic cleavage of the P1 capsid precursor polyprotein between two separate glutamine-glycine (QG) amino acid pairs by the viral protease 3CD. In this study, we have investigated the effects on P1 polyprotein processing and subsequent assembly of processed capsid proteins caused by substitution of the glycine residue at the individual QG cleavage sites with valine (QG->QV). P1 cDNAs encoding the valine substitutions were created by site-directed mutagenesis and were recombined into wild-type vaccinia virus to generate recombinant vaccinia viruses which expressed the mutant P1 precursors. The recombinant vaccinia virus-expressed mutant P1 polyproteins were analyzed for proteolytic processing defects in cells coinfected with a recombinant vaccinia virus (VVP3) that expresses the poliovirus 3CD protease and for processing and assembly defects by using a trans complementation system in which P1-expressing recombinant vaccinia viruses provide capsid precursor to a defective poliovirus genome that does not express functional capsid proteins (D. C. Ansardi, D. C. Porter, and C. D. Morrow, J. Virol. 67:3684-3690, 1993). The QV-substituted precursors were proteolytically processed at the altered sites both in cells coinfected with VVP3 and in cells coinfected with defective poliovirus, although the kinetics of cleavage at the altered sites were slower than those of cleavage at the wild-type QG site in the precursor. Completely processed capsid proteins VPO, VP3, and VP1 derived from the mutant precursor containing a valine at the amino terminus of VP3 (VP3-GO01V) were unstable and failed to assemble stable subviral structures in cells coinfected with defective poliovirus. In contrast, capsid proteins derived from the P1 precursor with a valine substitution at the amino terminus of VP1 (VP1-GOO1V) assembled empty capsid particles but were deficient in assembling RNAcontaining virions. The assembly characteristics of the VP1-GOO1V mutant were compared with those of a previously described VP3-VP1 cleavage site mutant (K. Kirkegaard and B. Nelsen, J. Virol. 64:185-194, 1990) which contained a deletion of the first four amino-terminal residues of VP1 (VP1-A1-4) and which was reconstructed for our studies into the recombinant vaccinia virus system. Complete proteolytic processing of the VP1-A1-4 precursor also occurred more slowly than complete cleavage of the wild-type precursor, and formation of virions was delayed; however, capsid proteins derived from the VP1-G001V mutant assembled RNA-containing virions less efficiently than those derived from the VP1-A1-4 precursor. These results demonstrate that maintenance of the glycine residues at the QG cleavage sites of the poliovirus P1 precursor is required for assembly and RNA encapsidation events in addition to proteolytic processing and provide further evidence that the amino-terminal portion of VP1 plays a role in the RNA encapsidation process of poliovirus.
Assembly of poliovirus virions requires proteolytic cleavage of the P1 capsid precursor polyprotein between two separate glutamine-glycine (QG) amino acid pairs by the viral protease 3CD. In this study, we have investigated the effects on P1 polyprotein processing and subsequent assembly of processed capsid proteins caused by substitution of the glycine residue at the individual QG cleavage sites with valine (QG->QV). P1 cDNAs encoding the valine substitutions were created by site-directed mutagenesis and were recombined into wild-type vaccinia virus to generate recombinant vaccinia viruses which expressed the mutant P1 precursors. The recombinant vaccinia virus-expressed mutant P1 polyproteins were analyzed for proteolytic processing defects in cells coinfected with a recombinant vaccinia virus (VVP3) that expresses the poliovirus 3CD protease and for processing and assembly defects by using a trans complementation system in which P1-expressing recombinant vaccinia viruses provide capsid precursor to a defective poliovirus genome that does not express functional capsid proteins (D. C. Ansardi, D. C. Porter, and C. D. Morrow, J. Virol. 67:3684-3690, 1993). The QV-substituted precursors were proteolytically processed at the altered sites both in cells coinfected with VVP3 and in cells coinfected with defective poliovirus, although the kinetics of cleavage at the altered sites were slower than those of cleavage at the wild-type QG site in the precursor. Completely processed capsid proteins VPO, VP3, and VP1 derived from the mutant precursor containing a valine at the amino terminus of VP3 (VP3-GO01V) were unstable and failed to assemble stable subviral structures in cells coinfected with defective poliovirus. In contrast, capsid proteins derived from the P1 precursor with a valine substitution at the amino terminus of VP1 (VP1-GOO1V) assembled empty capsid particles but were deficient in assembling RNAcontaining virions. The assembly characteristics of the VP1-GOO1V mutant were compared with those of a previously described VP3-VP1 cleavage site mutant (K. Kirkegaard and B. Nelsen, J. Virol. 64: [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] 1990 ) which contained a deletion of the first four amino-terminal residues of VP1 (VP1-A1-4) and which was reconstructed for our studies into the recombinant vaccinia virus system. Complete proteolytic processing of the VP1-A1-4 precursor also occurred more slowly than complete cleavage of the wild-type precursor, and formation of virions was delayed; however, capsid proteins derived from the VP1-G001V mutant assembled RNA-containing virions less efficiently than those derived from the VP1-A1-4 precursor. These results demonstrate that maintenance of the glycine residues at the QG cleavage sites of the poliovirus P1 precursor is required for assembly and RNA encapsidation events in addition to proteolytic processing and provide further evidence that the amino-terminal portion of VP1 plays a role in the RNA encapsidation process of poliovirus.
Poliovirus is the prototype member of the enterovirus group of the Picornaviridae, a family of icosahedral, nonenveloped plus-strand RNA viruses. The messenger sense poliovirus RNA genome is approximately 7.4 kb in length and contains a single open reading frame which is translated to generate a long polyprotein (25) . Virus-encoded proteases cleave the genomic polyprotein to release the individual viral proteins required for replication of the viral genome and assembly of progeny virions and therefore have an obligatory role in poliovirus morphogenesis (12, 40) . The viral protease 2A releases the structural proteins from the genomic polyprotein as a single 97-kDa precursor, designated P1, through an intramolecular cleavage event (40) . The mature virion proteins, VP1, VP2, VP3, and VP4, are released by further cleavages of the P1 precursor. Viral protease 3CD cleaves the peptide bonds between two glutamine-glycine (QG) amino acid pairs in the P1 polyprotein, releasing proteins VPO, VP3, and VP1 (12, 20, 42) . Upon capsid between an asparagine-serine (NS) amino acid pair to generate VP2 and a small capsid protein, VP4 (4, 18, 19, 38) . The cleavage of VPO is termed the maturation cleavage and is believed to be an intramolecular event (4) . The mature virion consists of 60 copies of VP3 and VP1 and nearly 60 copies of VP2 and VP4; a few residual copies of uncleaved VPO are believed to be present in the mature virion (38) . The genomelinked protein, VPg, is covalently linked to the viral RNA genome at its 5' end via a phosphodiester linkage with a tyrosine residue and is the only other viral protein in the mature poliovirion (41) .
Proteolytic processing of picornaviral P1 precursors is required for virus assembly and may be important for temporally controlling the different stages of the assembly process (14, 15, 32, 34) . The enzymatic activity of poliovirus protein 3Cpr0 is responsible for cleavage of the poliovirus P1 capsid precursor to generate protomers consisting of single copies of VPO, VP3, and VP1 (VPO-3-1)1 (12) . The 3CD polyprotein, which consists of uncleaved 3CP"°and 3DP"' proteins, is the form of 3CPro responsible for P1 cleavage (20, 42) . Although the determinants for cleavage site recognition by picornaviral 3CP(') enzymes have not entirely been identified, the primary sequence POLIOVIRUS P1 CLEAVAGE SITE MUTANTS 7285 of the dipeptide cleavage site is clearly important (9, 13, 22, 33, 34) . 3CPr"-mediated cleavages of poliovirus polyproteins occur exclusively at QG amino acid pairs (12, 25) . The 3CPr() enzymes of other picornaviruses, however, exhibit more flexibility in dipeptide recognition, although cleavage sites are typically composed of either glutamine or glutamic acid at the PI position of the bond to be cleaved and either glycine, serine, or alanine at the P1' position (33) . The importance of the amino acid constituents of 3CPr' cleavage sites has been extensively characterized for a member of the cardiovirus group of picornaviruses, encephalomyocarditis virus (EMCV). Studies of EMCV capsid precursor processing at the VP3-VP1 cleavage site by 3Cpr" enzymes in vitro demonstrated limited flexibility in the dipeptide recognition sequence, with only substitutions of the glycine residue of the wild-type QG cleavage site with amino acids containing small aliphatic side chains permitting cleavage of the peptide bond at the altered sites (34) . In addition to the primary sequence, the location of the cleavage site within the poliovirus polyprotein is important for accessibility to the enzyme (29, 43) , and the presence of an alanine residue at the -4 position relative to the cleavage site peptide bond has also been demonstrated to play an important role in site recognition for poliovirus (5, 31) .
The precise relationship between proteolytic processing of P1 and the capsid assembly process has not been completely defined. The amino termini of adjacent VP3 molecules form a n-cylinder structure on the interior of the icosahedral capsid at the fivefold axes of symmetry (16) . A concentric bundle formed from portions of the amino termini of VPO and VPI surrounds the f-cylinder structure. Because cleavage of P1 is required to free these termini, complete processing of P1 by the 3CD protease has been considered to be a prerequisite for capsid assembly, and this notion has been supported by studies of EMCV capsid protein processing and assembly with a cell-free in vitro system in which capsid precursors that were cleaved between VPO and VP3 but not between VP3 and VP1 failed to assemble (34) . Protomers consisting of single copies of the processed capsid proteins VPO, VP3, and VP1 assemble into subviral intermediate particles, including 14S pentamers (VPO-3-1)5 and 75S empty capsids or procapsids (VPO-3-1)6,0 (36, 38) . Formation of these particles can occur in the absence of full-length poliovirus RNA (la, 21, 36); however, it is not clear whether poliovirus RNA facilitates assembly of subviral intermediates. Both 14S pentamers and 75S empty capsids have been proposed to be the direct precursors to the mature virion, with the RNA encapsidation process proceeding by condensation of pentamers around the RNA genome or by threading of the RNA genome into an existing empty capsid (36, 38) (23) .
Insight into the poliovirus assembly process has been gained both from knowledge of the three-dimensional structure of the virus and from analysis of poliovirus capsid mutants by a variety of methods (14, 16) . Previous reports from our laboratory have described the use of recombinant vaccinia virusbased expression systems to study the poliovirus assembly process (la-3). Recently, we have demonstrated that poliovirus assembly can be analyzed by complementation of a capsid gene-deficient poliovirus RNA genome (11) by using recombinant vaccinia viruses to provide the type 1 poliovirus P1 precursor in trans (3) . In this report, we describe the analysis of poliovirus capsid protein mutants with valine substitutions for the glycine residues at the QG sites of the P1 precursor by using recombinant vaccinia viruses to express the mutant P1 precursors. We chose the valine substitutions because EMCV P1 precursors with the glycine-to-valine change at the QG cleavage site between VP3 and VPl were not substrates for cleavage by 3CPr" at the altered sites in vitro (34) , and the valine substitutions represented changes less drastic than substitutions with other amino acids with longer aliphatic side chains. Furthermore, a previous paper reported that a valine substitution at the QG cleavage site between 3C""r' and 3DP"I of poliovirus was lethal for virus growth, suggesting that QV could not serve as a functional cleavage site at that location (22) . Our initial aim was to use the recombinant vaccinia viruses expressing the QV-substituted P1 precursors to analyze the role, if any, of processing intermediates in assembly by using precursors that could be cleaved at only one site. Unexpectedly, we found that mutant P1 precursors were proteolytically processed at QV sites by 3CD protease provided in trans by a second recombinant vaccinia virus, although processing was hindered at the altered sites. The P1 precursors with QV cleavage sites were also completely proteolytically processed in cells coinfected with the recombinant vaccinia viruses and defective polioviruses which provide the capsid gene-deficient RNA genome. The assembly phenotypes of the QV mutants were compared with that of the previously described poliovirus capsid mutant with an amino-terminal deletion in VP1 (23, 24) , which was reconstructed for this study into the recombinant vaccinia virus expression system. The results of these studies demonstrate that mutations at the amino-terminal glycine residues of VP3 and VPI affect virus assembly and RNA encapsidation in addition to proteolytic cleavage and provide further evidence that the amino-terminal portion of the VP1 protein plays an important role in encapsidation of the poliovirus RNA genome (23) .
MATERIALS AND METHODS Chemicals and enzymes. All chemicals used for these studies were purchased from Sigma, unless otherwise specified. Enzymes used for DNA manipulations were purchased from New England Biolabs.
[35S]Translabel (methionine-cysteine) was purchased from ICN Biomedical. 355-dATP used for DNA sequencing and [ao-32P]UTP used for generating radiolabeled ribonucleotide probes (riboprobes) were purchased from Amersham.
Cells and viruses. HeLa cells were purchased from American Type Culture Collection and were maintained in monolayer culture in Dulbecco's modified Eagle medium (DMEM) (Gibco/BRL) supplemented with 5% fetal bovine serum (Biocell Laboratories) and the growth supplement GMS-G (Gibco/ BRL) (complete medium).
Vaccinia viruses used for these studies were cultured in either TK-14313 cells (American Type Culture Collection) or HeLa cells and were concentrated for experimental use by previously described methods (28) . Titers of vaccinia viruses were determined by plaque assay on HeLa cell monolayers. Poliovirus type 1 Mahoney used for these experiments was maintained in, and titers were determined by plaque assay on HeLa cell monolayers. Defective poliovirus preparations. The generation of defective poliovirus stocks by trans complementation of a poliovirus genome containing an in-frame capsid gene deletion has been described previously (3) . Defective polioviruses (PVdefSM) were maintained in HeLa cells coinfected with recombinant VOL. 67, 1993 7286 ANSARDI AND MORROW vaccinia virus VVP1 and were concentrated as previously described to remove residual infectious VVP1 in the preparations (3) . Preparations of defective poliovirus were plated on HeLa cell monolayers in serial dilutions to determine the minimum concentration required to infect every cell in a monolayer of 3 x 105 HeLa cells as determined by a poliovirus-like cytopathic effect after overnight infection. Because the defective polioviruses cannot initiate a second round of infection, a complete cytopathic effect after overnight incubation indicated initial infection of every cell in a monolayer. The minimum concentration of defective viruses resulting in a complete cytopathic effect was then used for experimental purposes.
Generation of recombinant vaccinia viruses expressing mutant P1 polyproteins. Recombinant vaccinia viruses expressing mutant P1 polyproteins were generated by previously described methods (la, 28). All DNA-subcloning procedures were performed by standard methods (39) . Site-directed mutagenesis of P1 cDNA was performed by hybridization of mutagenic oligonucleotides (purchased from Oligos, Etc.) to a single-stranded template DNA generated from the plasmid pUC119-P1. The plasmid pUC119-PI contains a cDNA copy of the poliovirus P1 gene flanked by Sall restriction sites and was derived by subcloning of the Sall insert from the previously described plasmid pSC1l-P1 (la, 6) into the unique Sall site of the pUCI 19 vector. The single-stranded DNA template was generated in the CJ236 (dut ung) strain of Escherichia coli to create a uracil-rich template to facilitate isolation of mutant cDNA plasmids (26) . Mutagenesis reactions were performed as previously described (44) . Plasmids harboring mutant P1 sequences were identified by dideoxy sequencing of the double-stranded DNA by using the Sequenase enzyme (U.S. Biochemical). pUCI 19-Pi plasmids containing mutant PI sequences were digested with Sall restriction enzyme to release the P1 gene insert, and the insert was subcloned into the unique Sall site of vaccinia virus recombination plasmid pSCII-Sal I (la, 6). Mutants encoding (i) a glycine-to-valine change at the amino terminus of VP3 (VP3-GOOIV), (ii) a glycine-to-valine change at the amino terminus of VPI (VPI-GOOIV), or (iii) a deletion of the first four amino acids of VPl (VPI-Al-4) were generated. The sequences of the oligonucleotides used for site-directed mutagenesis were as follows, with mismatched bases underlined: VP3-GOOIV, 5'-GC-TTA-CAG-GTG-CTG-CCG-GTC-3'; VPI-GOOIV, 5'-CTA-GCA-CAG-GTC-TTA-GGT-CAG-3'; and VP1-M1-4, 5'-GCG-CTA-
Recombinant vaccinia viruses were generated by transfec- Sucrose density gradient analysis of infected-cell extracts. Sucrose density gradient analysis of infected-cell extracts was carried out essentially as previously described (3). HeLa cell monolayers were coinfected with recombinant vaccinia viruses and PVdefSM and then incubated with [35S]Translabel for 2 h in methionine-cysteine-free DMEM, beginning 1.5 h postinfection with PVdefSM. Complete medium was then added to the monolayers with a further incubation of either 4 h or overnight. The infected monolayers were lysed by addition of Triton X-100 to the medium on the cells at a final concentration of 1%. The lysates were clarified by microcentrifugation and were layered over linear 15 to 30% sucrose density gradients prepared in a buffer of 10 mM Tris-HCl (pH 7.0), 10 mM NaCl, 1.5 mM MgCl2, and 0.01% bovine serum albumin. The sucrose gradients were centrifuged at 27,500 rpm for 4.25 h in a TH-641 rotor (Sorvall) at 4°C. Twenty fractions of 0.5 ml each were collected from the bottom of each gradient, and either even-or odd-numbered fractions were diluted with concentrated RIPA buffer and analyzed by immunoprecipitation for poliovirus capsid-specific proteins. Gradients were standardized for sedimentation of mature poliovirions (155S) and empty capsids (75S) by conducting a parallel gradient analysis of a lysate from poliovirus-infected cells which had been continuously incubated with [35S]Translabel from 3.5 to 8 h postinfection. Aliquots of each of the fractions from the poliovirus gradient were analyzed directly for radioactivity by liquid scintillation. The locations of mature virions and empty capsids in the poliovirus gradient were determined by the corresponding peaks of radioactivity.
Northern (RNA) blot analysis of encapsidated viral RNA. Poliovirus-specific RNA was detected by Northern blot analysis essentially as previously described (8) . Fractions 6 and 8 from sucrose density gradients were extracted with an equal volume of phenol-chloroform-isoamyl alcohol (25:24:1) , and RNA was precipitated by addition of LiCl and ethanol. Poliovirus virion RNA was extracted from a culture supernatant from poliovirus-infected cells to serve as a marker. The recovered RNA was separated on a 6.6% formaldehyde-0.8% agarose gel and transferred to a nitrocellulose membrane by capillary motion. The RNA was then hybridized to an in vitro-transcribed cx-32P-labeled riboprobe complementary to poliovirus plus-strand RNA between nucleotides 671 and 1I174 (8) . Following hybridization, the membrane was exposed to X-ray film at -70°C with an intensifying screen. 
RESULTS

Construction of recombinant vaccinia viruses which express
mutant P1 polyproteins. The construction and characterization of a recombinant vaccinia virus which expresses the poliovirus type I Mahoney capsid precursor polyprotein, P1, has been described previously (la). For the current studies, three new recombinant vaccinia viruses were generated, each of which expresses a mutant P1 precursor with an alteration at a site of proteolytic cleavage by the enzyme 3CD. Site-directed mutations encoding amino acid changes at sites of proteolytic cleavages were introduced into P1 capsid region cDNA (Fig.  1A) . The mutant P1 cDNAs were subsequently introduced into the wild-type vaccinia virus (WTVV) genome by homologous recombination to generate recombinant vaccinia viruses (la, 28). The mutations encoded a glycine-to-valine change at the amino terminus of VP3 (VP3-GOOIV) or at the amino terminus of VP1 (VP1-GOO1V). The third cleavage site mutation encoded a deletion of the first four amino-terminal residues of VP1 (VP1-zl-4) and has been described previously by Kirkegaard and Nelsen in the context of the full-length poliovirus genome (24) . This mutant was reconstructed for our studies by site-directed mutagenesis of P1 region cDNA and used to generate a recombinant vaccinia virus which expresses a P1 precursor containing the four-amino-acid deletion. The deletion results in the creation of a glutamine-methionine (QM) dipeptide which the previous study suggested could serve as the cleavage site between VP3 and VP1 (24) . All four mutant vaccinia viruses were shown to express the P1 precursor by metabolic radiolabeling and immunoprecipitation with poliovirus capsid-specific antiserum (Fig. IB) . Each P1 protein showed a similar degree of stability upon further incubation for an additional 4 h after labeling with excess unlabeled methionine and cysteine, indicating that the mutations introduced into the P1 polyprotein did not significantly affect stability of the unprocessed P1 precursor proteins. A slight decrease in stability of the VP1-A1-4 precursor relative to that of the other P1 precursors was observed in this experiment; however, in repeat experiments this has not been a consistent observation with the VP1-A1-4 mutant. Two additional proteins were detected by immunoprecipitation with antipoliovirus antiserum. One protein migrated slightly faster than P1 and was also immunoprecipitated from wild-type vaccinia virus-in- fected cells. A second protein migrating more slowly than P1 was not immunoprecipitated from wild-type vaccinia virusinfected cells by antipoliovirus antiserum but has also been detected by immunoprecipitation from cells infected with other recombinant vaccinia viruses generated by using plasmid pSC11 and is most likely the 3-galactosidase protein expressed as a selectable marker by these recombinants (data not shown).
Cleavage of mutant P1 polyproteins by 3CD protease provided by a separate recombinant vaccinia virus. Our initial aim in constructing the QV mutants was to generate P1 precursors that would be processed at only a single cleavage site. For our initial studies, the mutant P1 polyproteins VP3-GOO1V and VPI-GOO1V were analyzed for cleavage by the poliovirus protease 3CD by coinfecting cells with the recombinant vaccinia virus expressing the mutant P1 polyprotein and with a second recombinant vaccinia virus, VVP3, which expresses the poliovirus 3CD protease (Ia, 35) . Cleavage of the mutant polyproteins was compared with that of the wild-type P1 protein expressed in cells coinfected with VVPI and VVP3. Poliovirus capsid proteins generated in the recombinant vaccinia virus-coinfected cells were analyzed by immunoprecipitation after a pulse-chase radiolabeling experiment in which the coinfected cells were incubated with [35S]Translabel for 30 min and then subjected to a series of chase periods of up to 5 h in excess unlabeled methionine and cysteine (Fig. 2) . In cells coinfected with VVP1 and VVP3, complete proteolytic processing of the wild-type PI precursor expressed by VVP1 was evident from the appearance of the cleavage products VPO, VP3, and VP1 ( Fig. 2A) . VPO, VP3, and VPI were detected at the end of the 30-min labeling period (Fig. 2A, lane 1) , and there was continued accumulation of these proteins as chase times were extended ( Fig. 2A, lanes 2 to 7) . Intermediates of P1 processing, uncleaved VPO-VP3 (IABC) or uncleaved VP3-VP1 (ICD), were not detected at significant levels, indicating similar rates of processing at both QG cleavage sites in the P1 substrate. In contrast, formation of products of complete cleavage of both QV mutant P1 precursors was delayed in comparison with the formation of these products from wildtype P1 in cells coinfected with VVP3 and either VVP1-VP3-GOOIV or VVP1-VPI-GOOIV ( Fig. 2B and C uncleaved VPO-VP3 (IABC) were the major species of processed capsid proteins derived from the VP3-GOOIV mutant at the end of the pulse-labeling and at early chase harvests (Fig.   2B, lanes 1 to 3) . VPO and uncleaved VP3-VP1 (ICD) were the primary products detected at the end of the labeling period from cells coinfected with VVPI-VP1-GOOIV and VVP3 and at early chase harvests (Fig. 2C, lanes 1 to 3) . The (Fig. 2B, lane 8) . As chase times were extended, all three individual capsid proteins, VPO, VP3, and VP1, were gradually produced in cells coinfected with VVP3 and either mutant P1-expressing recombinant vaccinia virus (Fig. 2B and 2C,  lanes 4 to 7) . These results demonstrated that the glycine-tovaline changes at the QG processing sites delayed, but fected with WTVV and PVdefSM (Fig. 3, lanes 1 to 3) . 3CD expression also was not detected upon infection of cells with the extract from cells coinfected with VVP1-VP3-GOO1V and PVdefSM (lane 4). In contrast, 3CD expression was detected upon infection of cells with extracts derived from cells coinfected with VVP1-VPlGOO1V and PVdefSM (lane 5), VVP1-VP1A1-4 and PVdefSM (lane 6), or VVP1 and PVdefSM (lane 7). The level of 3CD expression resulting from infection of cells with the VVP1-VP1-GOO1V/PVdefSM extract was markedly lower than that from cells infected with either the VVP1-VP1-A1-4/PVdefSM or VVP1/PVdefSM extract. In serial passage experiments in which extracts from cells coinfected with PVdefSM and recombinant vaccinia virus were passaged two additional times with the same recombinant vaccinia virus, similar results were obtained: levels of 3CD expression from cells infected with the VVP1-VP1-A1-4/PVdefSM extract were similar to those from cells infected with the VVP1-VP1-A1-4/ PVdefSM extract, whereas a lower level of expression of 3CD from cells infected with the VVP1-VP1-GOO1/PVdefSM extract was detected (data not shown). Since formation of products of the complete cleavage of P1 precursors (VPO, VP3, and VP1) was observed in cells coinfected with the QV mutants and VVP3, although at reduced levels in comparison with wild-type P1, the lack of complementation observed with the VP3-GOO1V mutant and the reduced level of complementation observed for the VP1-GOO1V mutant suggested that the glycine-to-valine changes resulted in virus assembly defects in addition to slower polyprotein processing or resulted in production of noninfectious viruses. To investigate these possibilities, the mutant P1 polyproteins were further characterized by using the trans complementation system to determine where assembly defects might occur.
Proteolytic processing of mutant P1 precursors in the presence of a defective poliovirus genome. To facilitate identification of morphogenesis defects of the cleavage site mutants, proteolytic processing of the mutant P1 precursors and formation of mature poliovirus capsid proteins in cells coinfected with VVP1 mutants and PVdefSM were analyzed by metabolic protein radiolabeling and subsequent chase of radiolabeled proteins for defined time periods of 0.5 to 4 h or overnight (14 h). Preliminary experiments had determined that under the conditions used for this labeling experiment, the end of the chosen labeling period roughly corresponded to the time post-PVdefSM infection (approximately 3.5 h) at which proteolytic activity acting on P1 substrates expressed by recombinant vaccinia viruses could first be detected by immunoprecipitation. Poliovirus capsid-related proteins from the samples were analyzed by immunoprecipitation with antipoliovirus antiserum. Cleavage of P1 was not detected in cells infected with VVP1 alone (Fig. 4A, lanes 1 to 3) , and capsid-specific proteins derived from a full-length precursor were not detected in cells coinfected with WTVV and PVdefSM (Fig. 4A , lanes 4 to 6). In cells coinfected with VVP1 and PVdefSM, P1 was proteolytically processed by protease provided by PVdefSM to VPO, VP3, and VP1, as indicated by the appearance of these proteins at even the earliest harvests (Fig. 4B, lanes 1  to 3) . Cleavage products derived from the P1 precursor accumulated at up to 3 h of chase and then decreased slightly after chase times of 4 h or overnight, as determined by quantitation of levels of immunoprecipitated VP3 by phosphorimagery (Fig. 4B, lanes 1 to 8) . After a 1-h chase and subsequent chases, the mature virion protein VP2 was detected, indicating that the maturation cleavage of VPO associated with formation of mature virions had occurred (Fig. 4B,  lanes 3 to 8) .
Cleavage of mutant P1 precursors by protease provided by PVdefSM was analyzed in a similar manner and compared with the processing products derived from the wild-type precursor at different chase times. From cells coinfected with VVP1-VP3-GOO1V and PVdefSM, P1, VPO-VP3 (1ABC), and VP1 were the major capsid species detected at the end of the labeling period and at chase times of up to 2 h (Fig. 4C, lanes  1 to 5) ; however, after further incubation, complete proteolytic processing of some of the mutant precursors was evident from the appearance of VPO, VP3, and VP1 (lanes 6 to 8). Levels of completely processed proteins were quantitated by phosphorimagery for comparison with levels of proteins derived from wild-type P1. VP3 levels at each time were quantitated as an indicator of complete processing, since release of VP3 from the P1 precursor requires cleavage at both sites. VP3 derived from the VP3-GOO1V mutant precursor reached levels of 5% of that derived from wild-type precursor after 3 h of chase but dropped to approximately 1% of wild-type levels after an overnight chase. The decrease in levels of completely processed proteins detected after longer incubations indicated that the cleaved proteins derived from the VP3-GOO1V precursor were unstable.
Formation of cleavage products from complete cleavage of VP1-GOO1V precursors was reduced in comparison with that from the wild-type precursor, with less-frequent cleavage at the QV site between VP3 and VP1 apparent by the presence of an uncleaved VP3-VP1 (1CD) intermediate (Fig. 4D, lanes 1 . . was also detected, indicating that some of the VPl-GOOlV precursors were cleaved at the QV site first. Complete proteolytic processing was evident at 1.5 h of chase and thereafter by the appearance of VP3 (Fig. 4D, lanes 4 to 8) , and VP3 levels derived from this mutant reached 34% of those derived from wild-type P1 after the overnight chase period.
The P1 protein expressed by VVP1-VP1M-4 was proteolytically processed to individual capsid proteins VPO, VP3, and VPI, although, as with the VPIGOOIV mutant, an uncleaved VP3-VP1 (ICD) intermediate was detected, indicating lessfrequent cleavage between VP3 and VPI in comparison with that in the wild-type precursor. The four-amino-acid deletion resulted in a QM dipeptide at the cleavage site, and the generation of VP3 and VP1 from the VP1-AI-4 precursor lends support to the idea (24) that cleavage can occur between the glutamine and methionine residues (Fig. 4E, lanes I to 6) . VPO, VP3, and VP1 derived from this mutant were increasingly evident as chase times were extended (lanes 2 to 8), and after an overnight chase, VP3 levels reached 59% of those derived from wild-type P1 precursor. As with the VP1-GOO1V mutant, uncleaved VPO-VP3 was also detected, indicating that in some instances the VP1-GOOIV precursor was processed at the OM site prior to or in the absence of cleavage at the unaltered site between VPO and VP3.
Levels of the mature virion protein VP2 produced in the recombinant vaccinia virus-PVdefSM-coinfected cells were also compared quantitatively by phosphorimagery. Production of VP2 was observed from the wild-type precursor and from the VP1-GOOIV and VP1-A1-4 precursors but was not observed from the VP3-GOO1V precursor. The appearance of VP2 derived from the VP1-GOOIV and VP1-A1-4 precursors was delayed in comparison with that from the wild-type precursor. VP2 derived from the wild-type precursor was first observed after 1 h of chase (Fig. 4B, lane 3) ; that from the VP1-Al -4 precursor was first observed faintly after 2 h of chase (Fig. 4E, lane 5) , and that from the VPl-GOO1V precursor was first observed at low levels after 3 h of chase (Fig. 4D, lane 6 (Fig. 5A) .
Capsid proteins derived from the VP1-GOOlV and VP1-Al-4 mutants were analyzed after overnight incubation, whereas capsid proteins derived from the VP3-GOOIV mutant were analyzed 7.5 h postinfection with PVdefSM, since longer incubation times resulted in a decrease of radiolabeled processed proteins (Fig. 4C) . Consistent with the pulse-chase analysis of capsid proteins derived from the VP3-GOOIV precursor, we detected low levels of completely processed capsid proteins from cells coinfected with VVP1-VP3-GOOIV and PVdefSM. The VPO, VP3, and VP1 proteins were detected only in the upper fractions of the sucrose gradient (fractions 14 to 20) (Fig. SB) . Quantitation of VP3 levels in each fraction by phosphorimagery indicated that processed proteins were primarily localized from fractions 16 to 20 with lower amounts in fraction 14. Capsid proteins derived from this mutant were not detected in virion-corresponding fractions even upon overexposure of the gel depicted in Fig. 5B to X-ray film (data not shown). Although the presence of capsid proteins in fraction 14 suggested that some of the processed capsid proteins derived from this mutant might have assembled empty capsids, the instability of these proteins argues against the formation of stable assembly intermediates. In support of this idea, assembly of stable subviral intermediates derived from this mutant precursor was also not observed in cells coinfected with VVPI-VP3-GOOIV and VVP3, the recombinant vaccinia virus that expresses 3CD protease (data not shown).
In contrast to those from the VP3-GOOIV mutant, capsid proteins derived from the VP1-z1-4 and VP1-GOOIV precursors did assemble subviral intermediates and mature virions ( Fig. 6A and B) . For both of these mutants, VPO, VP3, and VPI accumulated in fractions consistent with the empty capsid peak on the poliovirus gradient (fractions 13 to 15), and primarily capsid proteins VP1, VP2, and VP3 were immunoprecipitated from fractions corresponding to the virion peak on the poliovirus gradient (fractions 5 to 9). These results demonstrated that capsid proteins derived from the VP3-VPI cleavage site mutant precursors were capable of forming mature virions. However, it was possible that fractions above the mature virion fractions might contain provirions that were not clearly resolved away from empty capsids in these gradients. To address this question, the sedimentation of capsid proteins derived from these mutants was compared with that of N069T expresses a P1 precursor with a threonine substitution for asparagine at the asparagine-serine cleavage site between VP4 and VP2. The VP4-N069T mutant precursor is deficient in the maturation cleavage of VPO and accumulates provirions or immature virions. Sucrose density gradient analysis of an extract from cells coinfected with VVP1-VP4-N069T and PVdefSM was performed to identify fractions containing the provirion particles (fractions 5 to 7) (D) Northern blot analysis of poliovirus-specific RNA extracted from sucrose density gradient fractions. RNA was extracted from gradient fractions 6 and 8 from the VP1-GOO1V, VP4-N069T and VP1-A1-4 gradients. The RNA was analyzed by Northern blot hybridization using a [32PJUTP-labeled riboprobe complementary to poliovirus plus-strand RNA from nucleotides 671 to 1174. Samples were derived from the VPI-GOOIV gradient (lane 1), the VP4-N069T gradient (lane 2), and the VPI-A1-4 gradient (lane 3). Lane 4 contains RNA extracted from type 1 poliovirus virions. Lanes 1 to 3 were exposed to X-ray film six times as long as lane 4. capsid proteins derived from a fourth capsid mutant which has a threonine substitution for asparagine at residue 69 of VP4 (VP4-N069T). This substitution occurs at the asparagineserine site of maturation cleavage of VPO; the corresponding mutation in human rhinovirus type 14 has been constructed and characterized by Lee et al. (27) and was demonstrated to result in an accumulation of provirions, or immature virions, in which RNA has been encapsidated but VPO has not been cleaved to VP2 and VP4. The details of the construction and characterization of the VVPI-VP4-N069T recombinant vaccinia virus will be presented elsewhere (1) . A sucrose density gradient analysis of a lysate from cells coinfected with VVP1-VP4-N069T and PVdefSM resulted in detection of a peak of VPO, VP3, and VP1 in fractions corresponding to the virion peak on the poliovirus gradient (Fig. 6C, fractions 5 to 7) . The use of this mutant, then, provided a marker for provirion particles for these gradient experiments and indicated that capsid proteins derived from the VP1-GOOIV and VP1-Al-4 mutants did not accumulate provirions. Finally, to confirm the identity of RNA-containing particle fractions, even-numbered fractions from the VP1-GOO1V, VP4-N069T, and VP1-A1-4 gradients corresponding to the mature virion peak from the poliovirus gradient were shown to contain poliovirus-specific RNA upon phenol-chloroform extraction and Northern blot analysis using a riboprobe complementary to poliovirus plusstrand RNA (Fig. 6D) . The RNA species detected from these fractions migrated slightly faster on the formaldehyde-agarose gel than full-length (35S) poliovirus RNA, consistent with the migration expected for the deletion-containing RNA genome (11) .
Although capsid proteins derived from both the VP1-GOOIV and VP1-A1-4 mutants assembled mature virions, significantly (Fig. 6B) were only 19% of VP3 levels in fraction 7 from the VP1-Xl-4 gradient (Fig. 6A) , as determined by phosphorimagery. Furthermore, the proportion of capsid proteins derived from the VPI-AI-4 precursor which sedimented into the mature virion-corresponding fractions relative to that in the empty capsid fractions was significantly higher than with the VPI-GOOIV mutant. The ratio of VP3 in virion fraction 7 to VP3 in empty capsid fraction 13 for the VP1-Al-4 gradient was 2.0, whereas the ratio for the VP1-GOOIV gradient was 0.4. This result was consistent with the results of the proteolytic processing analysis shown in Fig. 4 , in which considerably less VP2 formation was observed with the VPI-G001V mutant. Because the protein immunoprecipitation experiments shown in Fig. 6 were conducted on alternating gradient fractions only, a more thorough quantitative analysis of capsid protein distribution between virion and empty capsid fractions was performed to confirm the assembly defect observed for the VP1-GOOlV mutant. Sucrose density gradient fractionations were performed on lysates of metabolically radiolabeled, coinfected cells which had been allowed to incubate overnight. A parallel fractionation of an extract from radiolabeled poliovirus-infected cells was used to identify the mature virion and empty capsid peak fractions. Poliovirus capsid-specific proteins immunoprecipitated from virion and empty capsid fractions from each gradient were pooled and analyzed by SDS-PAGE (Fig. 7A) . The levels of VP3 protein recovered from virion and empty capsid fractions from each gradient were measured by phosphorimagery to compare the relative distribution of capsid proteins between virion and empty capsid fractions (Fig. 7B) . The levels of VP3 measured in empty capsid fractions derived from cells coinfected with PVdefSM and either VVP1, VVPI-VPI-A1-4, or VVPI-VP1-GOOV were very similar. In contrast, however, VP3 levels in virion fractions on the VPI-GOOIV gradient were markedly lower than those in the virion fractions from the VVP1 or VPI-A1-4 gradient. Levels of VP3 derived from wild-type P1 expressed by VVPI were found to be 3.3 times higher than levels in empty capsid fractions. In contrast, VP3 derived from the VP1-GO01V mutant was detected in virion fractions at a level of 0.38 times that in the empty capsid fractions. Thus, the proportion of capsid proteins in the empty capsid fractions relative to those in the virion fractions was essentially inverted when derived from the VP1-GOOIV mutant. The ratio of virion VP3 to empty capsid VP3 was approximately 2.2 when derived from the VP1-zA1-4 mutant. These results demonstrated that the capsid proteins derived from the VP1-GOOIV mutant were inhibited in formation of virions, since empty capsids were found in abundance over mature virion particles.
DISCUSSION
In this report, we have described the construction and characterization of poliovirus P1 capsid mutants with altered OG cleavage sites. The mutant P1 polyproteins were expressed by using recombinant vaccinia virus vectors and were analyzed for ability to trans complement a capsid gene-deficient poliovirus RNA genome delivered to the recombinant vaccinia virus-infected cells by coinfection with a preparation of poliovirus particles containing only the defective genomes (PVdefSM). In the trans complementation assay (Fig. 3) , the VP3-GOOlV mutant precursor failed to complement the defective genome, whereas the VP1-A1-4 mutant complemented at levels similar to those of the wild-type P1 precursor. The VP1-GOOIV precursor complemented the defective genome at levels markedly below those of either wild-type P1 or the VPI-Al-4 precursor. The levels of complementation observed in Fig. 3 were reflected in the differences in proteolytic processing, assembly, and encapsidation observed upon analysis of the products of cleavage of the mutant precursors. Mutant P1 polyproteins containing QV cleavage sites in place of QG sites were proteolytically processed at the altered sites by the viral protease 3CD, although processing at the altered sites was hindered. The VPO, VP3, and VP1 capsid proteins resulting from complete cleavage of P1 precursors with the VP3-GOOlV substitution did not assemble stable virions or subviral intermediates. The VPO, VP3, and VP1 proteins generated upon complete cleavage of P1 precursors with the VP1-GOOIV mutation were found to assemble empty capsids, but formation of virions was inhibited, and empty capsids derived from this mutant accumulated in abundance over virions in contrast to particles derived from wild-type P1.
Interestingly, the defect in virion formation observed for the VP1-GOOIV mutant was less evident when the first four amino acids of VPI were deleted (VPI-AI-4). These results demonstrate that the glycine-to-valine substitution at the amino terminus of VPI rendered capsid protomers defective for RNA encapsidation and that this effect was partially overcome by deletion of the first four amino-terminal amino acids of VP1. We were initially surprised to find that the P1 capsid precursors with QV cleavage sites were proteolytically processed at the altered sites, even with slower kinetics. The strict conservation of the QG cleavage sites in the poliovirus polyprotein (12, 25) suggested a limited flexibility for site recognition by poliovirus 3Cpr' enzyme or proteolytically active polyproteins that contain 3Cpro, such as 3CD. A previous study of proteolytic processing of EMCV capsid precursor by using a cell-free in vitro system found that a QV-substituted site at the VP3-VPI junction (QG is wild type) was not cleaved by 3CprO, nor were other mutant sites containing larger hydrophobic side chains at the P1' position (34) . The current study shows that the poliovirus 3CD protease can accommodate a valine side chain at the P1' position of the scissile bond, although processing at the QV sites occurs more slowly. This flexibility in the poliovirus Pl cleavage sites supports a previous study which suggested that a QM dipeptide created by deletion of the first four amino acids of VP1 could serve as the cleavage site between VP3 and VP1 (24) . It is possible that the QG site mutations constructed for this study diverted proteolytic cleavage to an alternative, more favorable site in nearby sequences. Amino acid pairs that would constitute alternative cleavage sites, however, are not readily apparent in the surrounding sequences. Obvious mobility shifts for processed proteins derived from the VP3-GOO1V and VP1-GOO1V precursors, which might have indicated aberrant processing, were not observed. As previously reported by Kirkegaard and Nelsen, the VP1 protein derived from cleavage of the VP1-A1-4 precursor did have an altered mobility; however, an altered mobility for the VP3 protein derived from this mutant was not observed (24) . If the slower migration of VPI derived from the VP1-A1-4 precursor was the result of additional sequences present because processing had occurred at an alternative site in the carboxy-terminal portion of VP3, a similar shift in migration might have been expected for VPl derived from the VPIGOOIV mutant if mutations at the QG cleavage site diverted proteolytic cleavage to an alternative bond. These studies suggest that a greater flexibility exists for substitutions of the P1' position of the QG cleavage sites in the poliovirus P1 precursor than for those of the EMCV P1 precursor. Alternatively, cleavage of the poliovirus PI precursor in vivo may be more efficient and more tolerant of cleavage site substitutions.
A previous report suggested that processing of the poliovirus P1 precursor protein is ordered, with processing occurring first at the VP3-VP1 bond, releasing VP1, followed by cleavage of the VPO-VP3 (IABC) intermediate (37) . Evidence for this cleavage order was based on the observance of a VPO-VP3 (IABC) intermediate but not a VP3-VP1 (ICD) intermediate from poliovirus-infected cells. Previous studies of picornaviral capsid precursor processing in vitro indicated that an obligatory order of cleavage does not exist for EMCV capsid precursor (34) . The results of the present study demonstrate that cleavage at the QG site between VP3 and VP1 is not obligatory for proteolytic processing to take place at the QG site between VPO and VP3 in the poliovirus P1 precursor, because a VP3-VP1 intermediate was readily detected as a product of cleavage of the VP1-GOOIV mutant precursor, demonstrating release of VPO without prior cleavage between VP3 and VP1. In addition, the overall rate of cleavage of P1 precursors to either partially (VPO-VP3 and VP1 or VPO and VP3-VP1) or completely (VPO, VP3, and VP1) cleaved products was similar for all of the mutant precursors and wild-type P1, providing further evidence that a less favorable cleavage site at one of the two locations did not significantly delay or preclude cleavage at the other site (data not shown). Whether the cleavage intermediates VPO-VP3 (1ABC) and VP3-VP1 (ICD) are substrates for 3CD protease or simply end products is not clear. The cleavage intermediates might be products of an abortive processing event which leaves cleavage intermediates that cannot serve as substrates for the enzyme. In vitro, the 3CD polyprotein has been identified as the protease responsible for efficient complete proteolytic cleavage of P1 to VPO, VP3, and VP1 (20, 42) , whereas 3Cpr"' cleaves the P1 precursor only at the cleavage site between VP3 and VP1 (30) . The in vitro cleavage of Pl to VPO-VP3 (lABC) and VP1 by 3CPr,) occurs inefficiently and only at high enzyme concentrations (30) . Whether this cleavage by 3CprO between VP3 and VPI occurs in vivo is unclear. An interesting speculation might be that cleavage of populations of P1 by mature 3CPr') rather than 3CD in poliovirus-infected cells results in production of VPO-VP3 and VPI and accounts for the observation of the VPO-VP3 intermediate from poliovirus-infected cells. In support of this idea, we did observe a VPO-VP3 cleavage intermediate from cells coinfected with VVP1 and PVdefSM, in which both 3CD and 3Cpr) should be present (Fig. 4B) ; however, in Fig.  2A , a VPO-VP3 intermediate from cells coinfected with VVP1 and VVP3, which expresses 3CD without further cleavage to 3CPro and 3DP"' (Ia, 35), was not as evident. Cleavage of the P1 precursor at both QG sites might occur in a single complex interaction event with 3CD enzyme, with incomplete cleavage leading to formation of substrates not recognized by the protease. Overall yields of completely processed proteins (VPO, VP3, and VP1) derived from each of the mutant precursors were reduced in comparison with those derived from wild-type Pl, suggesting that cleavage intermediates were unstable or were not further processed. Completely processed proteins derived from the mutant precursors might have arisen from situations in which complete cleavage of the precursors occurred in a single interaction event with enzyme.
Although the mutations introduced at the QG sites in the P1 capsid precursors hindered cleavage of the precursors, complete cleavage of a population of each of the mutant precursors was evident by formation of VP3, which can be released only upon cleavage at both of the sites acted on by 3CD in a common precursor protein. The VPO, VP3, and VPI proteins generated upon complete cleavage of the VP3-GOOIV mutant P1 polyproteins did not assemble empty capsids or virions at detectable levels. The VPO, VP3, and VPI products of complete cleavage of the VP3-GOO1V precursor were also unstable, and this instability is similar to that we have observed in previous studies of capsid proteins derived from a nonmyristylated poliovirus Pt precursor which are also defective in assembly (2, 3) . Assembly of 14S pentamers, empty capsids, and virions is most likely preceded by association of single copies of VPO, VP3, and VP1 to form 5S protomer or monomer building blocks of the capsid (38) . The 5S protomers may assemble from VPO, VP3, and VP1 derived from a common P1 precursor immediately after cleavage. In the case of the cleavage site mutants described in this report, we cannot distinguish whether VPO, VP3, and VPI which do arise from complete cleavage of the mutant P1 precursors are derived from events in which cleavage occurred at both the unaltered and mutant sites in a single interaction event with 3CD or whether products of complete cleavage arise from processing of VPO-VP3 or VP3-VP1 intermediates in subsequent interactions with 3CD. If formation of 5S protomers is dependent upon association of VPO, VP3, and VP1 derived from a common precursor immediately after cleavage, then a delay in cleavage at one of the two sites may preclude formation of 5S protomers and subsequently other capsid particles and virions. Thus, we might have expected capsid proteins derived from both the VP3-GOOIV and VPI-GOOIV precursors to be defec- is the result of a true assembly defect rather than being a consequence of the proteolytic cleavage defect precluding formation of 5S protomer subunits. The assembly defect of the VP3-GOOIV mutant might also imply that cleavage of the VPO-VP3 site first is required to generate functional protomers with properly arranged capsid proteins suitable for assembly.
Alternatively, the assembly incompetence of VPO-VP3-VP1
protomers derived from the VP3-GOOlV mutant might be the result of the valine substitution at the amino terminus of VP3. The adjacent VP3 N termini from the five protomers within a common pentameric subunit form a (3-cylinder structure which is apparently critical for weaving protomers together to form a pentamer (16) . The valine substitution at the amino terminus of VP3 might interfere with formation of the (3-cylinder and render capsid protomers incapable of forming stable pentamer subunits, thereby preventing further assembly. In contrast to capsid protomers generated from complete proteolytic processing of the VP3-GOOIV mutant, protomers derived from the VP1-GOOIV mutant did assemble capsid protein particles. However, the glycine-to-valine substitution at the amino terminus of VP1 apparently interfered with the RNA encapsidation process. A reduced level of VP2 derived from the VPI-GOOIV mutant was observed in comparison with that derived from the VP1-AI-4 or wild-type precursors. The reduced level of VP2 derived from this mutant was not the result of inefficient maturation cleavage of VPO derived from this mutant, since an increased presence of provirion particles derived from this mutant was not observed. The reduction in VP2 was thus an indicator of a defect in RNA encapsidation.
Interestingly, deletion of the first four amino acids of the VP1 amino terminus restored the capability of mutant protomers to form mature virions at levels near those of wild-type protomers, although accumulation of these particles was delayed in comparison with that of wild-type particles. The VP1-M1-4 mutant has previously been demonstrated to form mature virions with slower kinetics at a nonpermissive temperature of 39.5°C, whereas empty capsids formed normally (23) . Importantly, in our studies, the amino-terminal deletion in VPI delayed accumulation of completely processed proteins in comparison with wild-type precursor. The delay in virion formation observed with the VP1-z1-4 precursor by using the trans complementation system might reflect additional time required to generate sufficient pools of protomers for virion formation. Although this argument can certainly be applied to the VPI-GOOIV mutant, the difference in completely processed protein levels between the VP1-GOOIV and VPI-AI-4 mutants was much less pronounced than differences in virion formation, and completely processed proteins derived from the VP1-GOOIV mutant assembled comparable levels of empty capsids (Fig. 7) . The results of this study, then, provide further evidence that the amino terminus of VP1 plays an important role in the RNA encapsidation process. The amino-terminal residues of VPI, which were disordered in the three-dimensional structure of poliovirus, have been modeled as an amphipathic helical structure (10) . Previous reports have also implicated this region in the processes of RNA release (10, 23) .
Thus, the amino terminus of VPI may play an active role in manipulating the poliovirus RNA genome during the processes of encapsidation and uncoating, and mutations in this structure may interfere with the mechanisms involved in these processes.
In summary, the results of this study demonstrate that conservation of the glycine residues at the PI' positions of the 3CD cleavage sites in the poliovirus P1 precursor is required for assembly functions in addition to efficient proteolytic processing of the precursor. A valine substitution at the amino terminus of VP1 interfered with the formation of RNAcontaining virions, whereas empty capsids accumulated at levels similar to those in cells coinfected with VVPland PVdefSM. These results suggest that the amino terminus of VPI directly interacts with the RNA genome or influences the structure of another determinant required for the encapsidation process. Clearly, determinants in addition to the aminoterminal residues of VPI are important for RNA encapsidation. Further studies will be needed to define the role of the amino-terminal residues of VP1 and other poliovirus capsid determinants in the encapsidation process.
